Current Report Filing (8-k)
August 03 2021 - 05:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest event reported): July 28, 2021
Medicine Man Technologies, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Nevada |
001-36868 |
46-5289499 |
(State
or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
4880 Havana Street, Suite 201 Denver, Colorado
80239
(Address of Principal Executive
Offices) (Zip Code)
(303) 371-0387
(Registrant’s Telephone Number,
Including Area Code)
Not Applicable
(Former Name or Former Address, if
Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of Each
Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which
Registered |
Not applicable |
|
Not applicable |
|
Not applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 1.01. Entry into a Material Definitive Agreement.
On July 28, 2021, Mesa Organics Ltd, a wholly-owned subsidiary of
Medicine Man Technologies (the “Company”), in its capacity as the
administrative borrower, entered into a First Amendment to Loan
Agreement (the “Amendment”) with SHWZ Altmore, LLC, as lender (the
“Lender”), and GGG Partners LLC, as collateral agent (the
“Collateral Agent”), effective as of June 25, 2021. The Amendment
amended two definitions in the Loan Agreement, dated February 26,
2021, among Mesa Organics Ltd., Mesa Organics II Ltd., Mesa
Organics III Ltd., Mesa Organics IV Ltd., SCG Holding, LLC and PBS
Holdco LLC (collectively, the “Borrowers”), the Lender and the
Collateral Agent (the “Loan Agreement”), to extend the time period
during which the Borrowers are eligible to request the final
$5,000,000 advance under the Loan Agreement by 60 days, or until
August 25, 2021.
On July 28, 2021, the Lender made the final advance of $5,000,000
to the Borrowers under the Loan Agreement. As previously reported,
the final advance was conditioned on, among other things, the
Company’s completing its asset purchase from SCG Services, LLC,
which occurred on July 21, 2021 as previously reported in the
Company’s Current Report on Form 8-K filed July 27, 2021.
The foregoing description of the Amendment is qualified in its
entirety by reference to the full text of the Amendment, a copy of
which is attached hereto as Exhibit 10.1 and incorporated herein by
reference. The Company previously reported the terms of the Loan
Agreement and the other transaction documents entered into in
connection with the Loan Agreement in the Company’s Current Report
on Form 8-K filed March 4, 2021.
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.
The information included in Item 1.01 of this Current Report on
Form 8-K is hereby incorporated by reference into this Item
2.03.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
MEDICINE MAN TECHNOLOGIES,
INC. |
|
|
|
By: |
/s/ Daniel R.
Pabon |
Date: August 3, 2021 |
|
Daniel R. Pabon
General Counsel |
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2022 to May 2022
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From May 2021 to May 2022